AstraZeneca's global biologics R&D arm MedImmune and the University of Cambridge have entered into a three-year oncology research collaboration in order to advance cancer research by using imaging technologies to measure key biologic changes within growing tumors.
SUBSCRIBE
Biohealth Innovation
Founding Member of
